Medical Advocates
HCV Infection/Disease
  Investigational Drugs  
General Reports|
 Cannabinoids
Anti-tumor Necrosis Factor-alpha
HEP1
 Levovirin
Resiquimod
Thymosin alpha1
 Viramidine
 VX-950



 




 
HCV Main Page Main New/Newsworthy HCV Drugs Home Page      

Last Update:  February 03, 2008
 Documents identified with this icon are in Portable Document Format (PDF) and require the Adobe Acrobat Reader

General Reports
 

      Conference Reports, Abstracts, and Posters
 

  CONFERENCE PRESENTATION
 Future Therapy of Hepatitis C
McHutchison JG
 [NIH Consensus Development Conference on  Management of Hepatitis C: 2002]
 Report
Anti-tumor Necrosis Factor-alpha
 

      Journal Papers, Abstracts, and Commentaries

  Etanercept treatment for three months is safe in patients with rheumatological
manifestations associated with hepatitis C virus.
 Marotte H, Fontanges E, Bailly F, et al   
Rheumatology (Oxford). 2006 May 23;
 Abstract
Cannabinoids
 

      Journal Papers, Abstracts, and Commentaries

  Reefer madness? Assessing the effects of cannabinoids with a less jaundiced eye
 Friedman SL.
J Hepatol. 2006 Oct 30;
 Abstract
HEP1
 

     Journal Papers, Abstracts, and Commentaries

  Treatment of hepatitis C virus infection with human ezrin peptide one (HEP1) in HIV infected
patients.
Salamov G, Holms R, Bessler WG, Ataullakhanov R.
Arzneimittelforschung. 2007;57(7):497-504.
 Abstract
Levovirin
 

      Journal Papers, Abstracts, and Commentaries

  Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved derivatives
of ribavirin.
 Watson J.
Curr Opin Investig Drugs 2002 May;3(5):680-3  
Abstract
Resiquimod
 

      Journal Papers, Abstracts, and Commentaries

  Oral resiquimod in chronic HCV infection: Safety and efficacy in 2 placebo-controlled,
double-blind phase IIa studies
 Pockros PJ, Guyader D, Patton H, Tong MJ, et al
J Hepatol. 2007 May 4;
Abstract
Thymosin alpha1
 

      Journal Papers, Abstracts, and Commentaries

  Thymosin alpha1
 Billich A.
Curr Opin Investig Drugs 2002 May;3(5):698-707
 Abstract   
VX-950
 

      Journal Papers, Abstracts, and Commentaries

  Prospects for hepatitis C virus therapeutics: levovirin and viramidine as improved
derivatives of ribavirin.
 Watson J.
 Curr Opin Investig Drugs 2002 May;3(5):680-3  
Abstract
Viramidine
 

      Journal Papers, Abstracts, and Commentaries
  Rapid Decline of Viral RNA in Hepatitis C Patients Treated With VX-950: A Phase Ib,
Placebo-Controlled, Randomized Study.
 Reesink HW, Zeuzem S, Weegink CJ, et al
Gastroenterology. 2006 Oct;131(4):997-1002.
 Abstract

HCV Main Page Main New/Newsworthy HCV Drugs Home Page      

HCV Investigational Drugs